Back to Search
Start Over
Tildrakizumab use for recalcitrant pityriasis rubra pilaris.
- Source :
-
Australasian Journal of Dermatology . Aug2024, Vol. 65 Issue 5, p476-479. 4p. - Publication Year :
- 2024
-
Abstract
- This article discusses the use of tildrakizumab, an interleukin (IL) inhibitor, for the treatment of recalcitrant pityriasis rubra pilaris (PRP). PRP is a rare skin disorder with no approved biologic treatments in Australia. The article presents three cases of PRP that were successfully treated with tildrakizumab, resulting in significant improvements in symptoms and minimal adverse effects. Tildrakizumab is considered a promising therapeutic option for PRP, and further studies are needed to determine its optimal use. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00048380
- Volume :
- 65
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Australasian Journal of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 178994606
- Full Text :
- https://doi.org/10.1111/ajd.14307